In case you missed any, below is a recap of every episode of OncLive On Air^® that aired in May 2024. Check out our podcast page for a full episode lineup and to stay up-to-date with all of the latest releases!

Merkow and Connell Highlight Considerations for HAI Pump Use in CRC

In this exclusive conversation, Ryan Merkow, MD, MS, of the University of Chicago Medicine Comprehensive Cancer Center and Cancer Service Line in Illinois and Louise Catherine Connell, MB BCh BAO, BMedSc, of Memorial Sloan Kettering Cancer Center in New York, New York, discussed the use of hepatic artery infusion (HAI) therapy as a treatment approach for patients with colorectal cancer (CRC), characteristics of patients who may be good candidates for this treatment, and more.

“One of the fundamental reasons why we treat any patients is to help them,” Merkow said. “We have a variety of therapies, and for patients with CRC, when it metastasizes to the liver, we know, with a very high degree of certainty, that if we can manage what happens in the liver, if we can control the disease, and in many cases, get patients to complete clearance of all disease in the liver, those patients are going to do better than patients [in whom] we cannot do that. HAI therapy is a tool that fits into our armamentarium to achieve those goals.”

“In addition to the data, it’s truly [impressive] seeing the examples of patients coming into the clinic who benefit from this,” Connell emphasized.

Goy Gives Insights Into the Future Management of Lymphoma and Multiple Myeloma

In this interview, Andre H. Goy, MD, of John Theurer Cancer Center at Hackensack University Medical Center in New Jersey, highlighted the importance of CAR T-cell therapy in the lymphoma and multiple myeloma treatment paradigms and his predictions for the future of hematologic oncology.

“When I went into the field of oncology, I thought it would be [in] the most dynamic specialty and address the most important challenges of cancer,” Goy shared. “I didn’t expect it would move that fast, but we have seen this continuing over the last 10 years with the replacement of chemotherapy with combination therapy. We talk about T-cell engagers, and CAR T-cell therapy has dramatically changed things and is going to continue to completely revolutionize the way we think of cancer.”

Kummar on the Investigation of Rezatapopt in TP53 Y220C–Mutated Advanced Solid Tumors

In this exclusive interview, Shivaani Kummar, MBBS, FACP, of Oregon Health & Science University School of Medicine in Portland, discussed the importance of targeting TP53 Y220C in solid tumors, efficacy and safety data with rezatapopt (PC14586) in TP53 Y220C–mutant solid tumors, and the future development of TP53-directed drugs both as a monotherapy and in combination regimens.

“I’ve been doing drug development for over 20 years, and I find that this point is one of the most exciting times in this field, as we now have the ability to specifically design molecules against molecular targets within cancer cells, as well have a slew of different types of agents that target the tumor microenvironment in immune cells,” Kummar emphasized.

Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer

In this episode, Jubilee Brown, MD, of Atrium Health Levine Cancer Institute in Charlotte, North Carolina, explained the role of the RAS/MAPK pathway in the development of low-grade serous ovarian cancer, unmet needs for patients with this disease, and the ongoing phase 3 RAMP-301 trial (NCT06072781) that is investigating the combination of avutometinib (VS-6766) and defactinib (9VS-6063) in this patient population.

“The RAMP-301 trial is exciting because it is a targeted trial,” Brown said. “It is absolutely driven to get at the heart of the mechanism of response of what drives these tumors. We’re going to target the pathway that’s overexpressed and target the pathway that’s the driver for the development of these tumors.”

Camidge and Arslan Calculate the “Impact Factor” of a Career in Medicine

In this episode of How This Is Building Me, host D. Ross Camidge, MD, PhD, was joined by İlker Arslan, MD, of AstraZeneca, who shared his experience providing emergency medical care around the world, expanded on why he pursued a career in this industry, and the excitement he feels when drugs he is involved in the development of make a difference for patients.

“Medical education gives you the power and capabilities of going beyond,” Arslan said. “You just diagnose something and find a solution. It doesn’t have to be a medical thing.”

“You have to change specialty thinking in pharma, sometimes changing on a dime, but you had all the practice in that,” Camidge said of Arslan.

Ganjoo Discusses Treatment Plans, Patient Conversations, and the Role of Nab-Sirolimus in Malignant PEComa

In this exclusive interview, Kristen N. Ganjoo, MD, of Stanford Health Care in California, highlights unmet needs for patients with advanced malignant perivascular epithelioid cell tumors (PEComa), considerations when creating a treatment plan for these patients, and how to have productive discussions with patients about adverse effects that are associated with nab-sirolimus (Fyarro).

“The first important thing is the expert consultation to review the pathology to make sure we’re dealing with a PEComa, and then [we can consider] treatment recommendations,” Ganjoo emphasized.

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

In this exclusive commentary, experts from a variety of oncology specialties highlight the abstracts and presentations they are excited to see at the 2024 ASCO Annual Meeting.

“At the 2024 ASCO Annual Meeting, we’re expecting a wide range of data. The plenary session will feature the [phase 3] LAURA trial [NCT03521154], looking at the role of consolidation osimertinib [Tagrisso] after chemoradiation, [which could] change practice overnight,” Stephen Liu, MD, of the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC, stated regarding key updates in lung cancer that he is looking forward to.

“The [phase 3 postMONARCH trial (NCT05169567)] data may be practice changing because it is a phase 3 clinical trial, so if the results are positive, depending on the magnitude of positivity, [abemaciclib (Verzenio) plus fulvestrant (Faslodex)] could become a therapy that we use in that second-line [hormone receptor–positive, HER2-negative breast cancer] setting,” Sara A. Hurvitz, MD, FACP, of Fred Hutchinson Cancer Center in Seattle, Washington, added in her review of upcoming breast cancer data.

“With the newly diagnosed randomized trials, one of the things I’ll be watching out for is that these trials are looking at quadruplet treatments in patients who are not transplant eligible. It’ll be interesting data in terms of efficacy as well as safety,” S. Vincent Rajkumar, MD, of Mayo Clinic in Rochester, Minnesota, emphasized about the multiple myeloma research being presented at the meeting.

“ASCO is always a forum in which we see the latest and greatest cutting-edge data. In my field, kidney cancer, the biomarker work that is going to be presented there is more voluminous than anything I’ve seen in previous meetings,” Sumanta Kumar Pal, MD, FASCO, of City of Hope in Duarte, California, emphasized when speaking to the genitourinary cancer findings he is excited to see.

“I’m just excited to learn more. We’ll see what the data are once they’re all presented. Who knows? They could be positive or negative. When these are presented, we’ll know a bit more details about how to parse the results,” Shubham Pant, MD, MBBS, of The University of Texas MD Anderson Cancer Center in Houston, explained regarding the gastrointestinal cancer research he is looking forward to learning more about.

Camidge and Datta Detail the Career of an “Opportunistic Nomad”

In this episode of How This Is Building Me, host D. Ross Camidge, MD, PhD, sat down with Jashodeep Datta, MD, of the University of Miami Sylvester Comprehensive Cancer Center in Florida, to discuss Dr Datta’s career as a surgeon-scientist, the similarities between music and surgery, and research that aims to improve systemic therapies for pancreatic cancer that will in turn benefit surgical operations.

“Dr Datta is a really interesting guy who straddles multiple different worlds,” Camidge emphasized.

“Think about every patient as a way to learn something about the disease,” Datta emphasized to his fellow surgeon-scientists. “If you do that, the world is your oyster. Science will come because the best scientific questions stem from the most insightful clinical observations.”

Levy Lends Insights Into the Current and Future Use of ADCs in NSCLC

In this exclusive interview, Benjamin Levy, MD, of the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital in Washington, DC, explained the current role of fam-trastuzumab deruxtecan-nxki (Enhertu) in the treatment of patients with HER2-mutant non–small cell lung cancer (NSCLC), other antibody-drug conjugates (ADCs) in development for patients with lung cancer, and what the future of ADCs in NSCLC may look like.

“We’re learning more and more about ADCs, and it’s exciting to see the field evolve,” Levy emphasized.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.